Zogenix, Inc. (ZGNX) Physician Survey Indicates Dravet Could Be Best in Class - Stifel

Stifel analyst Paul Matteis reiterated a Buy rating and $68.00 price target on Zogenix, Inc. (NASDAQ: ZGNX) after conducting an epilepsy physician survey that suggests that ZGNX shares are undervalued on the potential of Fintepla in Dravet and LGS. The survey group consisted of 25 epileptologists/neurologists who treat 11,400 epilepsy patients, including 480 and 1209 with Dravet and LGS, respectively.

The analyst stated "Feedback on Dravet, even though familiarity with Fintepla is still variable is generally affirming to this being a best-in-class drug. Physicians are projecting slightly over 50% penetration at peak; those who stated they know the data "very well" expect Fintepla to be utilized in 54% of their Dravet patients, and in the aggregate respondents expect 18%/32% of Dravet patients on drug at 6/12 months".

For an analyst ratings summary and ratings history on Zogenix, Inc. click here. For more ratings news on Zogenix, Inc. click here.

Shares of Zogenix, Inc. closed at $27.40 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)